Cough syrup, a medicated and flavored liquid, has become a staple in alleviating coughs and soothing irritated throats caused by respiratory illnesses, bronchitis, and common colds. The market for cough syrup is witnessing growth trends driven by various factors, including the increasing incidence of respiratory disorders, rising air pollution, a growing geriatric population, and the robust pharmaceutical sector. However, challenges such as product recalls and a stringent regulatory landscape are impacting market growth.
One of the prominent contributors to the expansion of the cough syrup market is the escalating prevalence of respiratory disorders. This trend is closely linked to factors such as environmental pollution and the changing lifestyle patterns of individuals. As respiratory ailments become more commonplace, the demand for effective cough syrups is on the rise.
The aging global population is another key factor propelling the growth of the cough syrup market. The elderly are particularly susceptible to respiratory disorders, and as the world witnesses an increase in the geriatric demographic, the demand for cough syrups is expected to surge. Additionally, the pharmaceutical sector's strength plays a pivotal role in market growth, with research and development efforts contributing to innovative product developments.
Despite these growth drivers, challenges exist in the form of product recalls and a stringent regulatory environment. Regulatory requirements for pharmaceutical products, including cough syrups, demand a high standard of safety and efficacy, leading to rigorous testing and scrutiny. While these regulations ensure product quality, they can also pose obstacles for market players.
The global cough syrup market is poised for substantial growth, with projections estimating it to reach USD 5,139.63 million by 2026, reflecting a Compound Annual Growth Rate (CAGR) of 3.45% from 2019 to 2026. In 2018, the Americas dominated the market with a 32.4% share, followed by Europe at 31.3% and Asia-Pacific at 29.2%. The Americas' leadership can be attributed to an increasing prevalence of respiratory disorders and the availability of advanced medications for conditions like Chronic Obstructive Pulmonary Disease (COPD).
Looking at market segmentation, cough suppressants claimed the largest market share of 89.6% in 2018, reaching USD 3,513.87 million. This category is projected to register the fastest CAGR of 3.50% during the forecast period. On the application front, the adult segment is anticipated to witness a higher CAGR of 3.37%. The rising adult population affected by respiratory disorders, coupled with the growing geriatric demographic, is driving the demand for cough syrups among adults. Major market players like Pfizer and Novartis are actively focusing on developing cough syrups tailored for adults, further stimulating market growth.
In conclusion, the global cough syrup market is navigating a path of growth, fueled by factors such as the increasing prevalence of respiratory disorders and a burgeoning aging population. While challenges exist, the market's trajectory remains positive, with ongoing research and development efforts poised to contribute to its expansion.
Report Attribute/Metric | Details |
---|---|
Market Size Value In 2022 | USD 4.9 Billion |
Market Size Value In 2023 | USD 5.07 Billion |
Growth Rate | 3.60% (2023-2032) |
Cough Syrup Market Size valued at USD 5.07 Billion in 2023. The Cough Syrup market industry is projected to grow from USD 5.25 Billion in 2024 to USD 6.7 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 3.09% during the forecast period (2024 - 2032).Increased respiratory diseases and concerns related to self-care, and rising air pollution are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Market CAGR for cough syrup is being driven by rising respiratory diseases. The growing number of respiratory diseases have increased the growth of the cough syrup market. The rising geriatric population and enormous air pollution keep boosting market growth. Chronic respiratory diseases like the chronic obstructive pulmonary disease and asthma mainly lead to major variations in morbidity and mortality throughout the different regions. The development and innovations of new and natural cough syrups for kids are being done.
The cough syrups are advised by the doctors or available over-the-counter for patients suffering from sneezing, runny nose, common cold, and other respiratory allergies. The cough syrup ingredients have properties of pro-viral, and according to scientists, they should not be consumed by people infected by the virus. The cough syrups include antihistamines and non-opioids that work on the center of coughs in the brain and stop the histamines that are released naturally, which causes allergies. The cough syrups assist in relieving dry and wet coughs with runny and thick mucus. The growth in geriatric population and the sedentary lifestyles of the population are causing the rise in bad habits like smoking addiction which can lead to respiratory, lung disease, and throat, thus boosting the market. In order to develop cough syrups that are safe for kids and have lesser side effects with ingredients that are natural, advancements and innovations are also being made. The manufacturers are innovating variants fortified with natural herbs and ingredients that have immunity-boosting properties. The increasing expenditure abilities of the consumers and significant growth in the industry of pharmaceutical is expected to boost the market.
The increasing levels of air pollution levels lead to more respiratory diseases, which are the main concern of the governments of different nations, thus boosting the market growth. As per the United Nations Environmental Program report, there are around 7 million premature deaths happening across the world because of air pollution, and almost 99% of the population in the world lives in areas where the air pollution guidelines produced by WHO are not met. Thus, driving the Cough Syrup market revenue.
The Cough Syrup market segmentation, based on type, includes Expectorants, Cough Suppressants, Antihistamines, and Combination Medications. The cough suppressants segment dominates the market, accounting for the largest market revenue due to the wide range of awareness and applications for cough syrups as a medication for cough. Cough syrups are predominantly considered for wet and dry coughs, though all of its other benefits are secondary and not known well. It is also the most commonly available dextromethorphan at pharmacies or stores.
The Cough Syrup market segmentation, based on distribution channels, includes Retail Pharmacies, Hospital Pharmacies, ad Online Pharmacies. The retail pharmacies segment dominates the market due to the fact that the common cold and flu or cough are very basic problems, and often people do not choose to go to the doctor when it's not very severe and prolonged. Over-the-counter cough syrups are taken by most of the population which do not require prescriptions. Hence a lot of revenue is made by the retail stores from this market. Furthermore, with the growing awareness among the population, it is anticipated that the online pharmacy segment is going to witness healthy growth.
Figure 1: Cough Syrup Market, by Distribution Channel, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Cough Syrup market dominates the market due to the presence of different significant key market players. The growing cases of respiratory diseases with the availability of treatment for chronic diseases are some of the reasons that are fueling the cough syrup industry's growth in the North American region.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: Cough Syrup MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe's Cough Syrup market accounts for the second-largest market share due to the availability of different giant market players and the growth of pharmaceutical industries in this region. Further, the German Cough Syrup market held the largest market share, and the UK Cough Syrup market was the rapid-growing market in the European region.
The Asia-Pacific Cough Syrup Market is expected to grow at the fastest CAGR from 2024 to 2032. This is with the increase in the elderly population, the high prevalence of respiratory disorders, and the prevalence of asthma diseases due to air pollution. Moreover, China’s Cough Syrup market held the largest market share, and the Indian Cough Syrup market was the rapid-growing market in the Asia-Pacific region.
Cough Syrup Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to spread their product lines, which will help the Cough Syrup market grow even more. Market participants are also undertaking a various strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the Cough Syrup industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Cough Syrup industry to benefit clients and increase the market sector. In recent years, the Cough Syrup industry has offered some of the most significant advantages to medicine. Major players in the Cough Syrup market, including Johnson and Johnson Services, Inc, Zarbee's Natural, Merck & Co. Inc, Pfizer Inc., Procter and Gamble, Reckitt Benckiser Group PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline PLC, Acella Pharmaceuticals LLC, Sanofi, and others, are attempting to increase market demand by investing in research and development operations.
Pfizer Inc., established in 1849, headquartered at The Spiral in Manhattan, New York City, is an American multinational pharmaceutical and biotechnology corporation. The company develops and manufactures medicines and vaccines for oncology, immunology, cardiology, neurology, and endocrinology. The Pfizer-BioNTech Covid-19 vaccine, Nirmatrelvir/ritonavir, a pneumococcal conjugate vaccine, and Palbociclib are the company's largest products by sale. 42% of the company's revenues came from the United States, 8% from Japan, and 50% from other countries, in the year 2022. In December 2016, Pfizer Inc. launched different products to expand its product line under the sub-brand name Corex. Initially launched in 2016, but later, the launch was done in 2017. The state and center regulators have duly proved all the product formulations.
Merck & Co. Inc., headquartered in Rahway, New Jersey, is an American multinational pharmaceutical company. It's one of the largest pharmaceutical companies in the world. They develop and manufacture vaccines, medicine, biological therapies, and animal health products. It has various blockbuster drugs or products, including cancer immunotherapy, vaccines against HPV and chicken pox, and anti-diabetic medication. In February 2019, the research and development facility was expanded by Merck in Billerica, Massachusetts. They invested USD 70 million to develop a robust clinical pipeline, which highlights the requirement to always be up and about in terms of product development and innovation.
Key Companies in the Cough Syrup market include
Cough Syrup Industry Developments
March 2022:KaraMD announced Pure Health Apple Cider Vinegar Gummies, a vegan gummy aimed to aid ketosis, digestion regulation, weight management, and encourage greater levels of energy.
January 2022:Solace Nutrition, a US-based medical nutrition company, bought R-Kane Nutritionals' assets for an unknown sum. This asset acquisition enables Solace Nutrition to develop synergy between both brands, accelerate growth, and establish a position in an adjacent nutrition sector. R-Kane Nutritionals is a firm established in the United States that specializes in high-protein meal replacement products for weight loss.
February 2021: Johnson and Johnson acquired Zarbee's Naturals; this acquisition helped with demand for natural cough syrups for kids, which also helped Johnson and Johnson to diversify its portfolio.
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)